- Home
- PBM
as 11-15-2024 4:00pm EST
Stocks
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
| Founded: | 1994 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 4.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 8.8M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.05 - $14.55 | Next Earning Date: | 11-29-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest PSYENCE BIOMEDICAL LTD News
PBM Breaking Stock News: Dive into PBM Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
GlobeNewswire
18 days ago
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
GlobeNewswire
18 days ago
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
GlobeNewswire
24 days ago
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
GlobeNewswire
25 days ago
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
GlobeNewswire
a month ago
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
GlobeNewswire
a month ago
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
GlobeNewswire
a month ago
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
Compare PBM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PBM PSYENCE BIOMEDICAL LTD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.